Search
for
Sort by
Research 30 of 1000+
- 5-Alpha Reductase Inhibitors in Prostate Cancer: From Clinical Trials to Clinical Practice
- Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs
- Side Effects of 5‐Alpha Reductase Inhibitors: A Comprehensive Review
- Long-term use of 5α-reductase inhibitors and the risk of male breast cancer
- Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors
- Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs
- Risk of rhabdomyolysis from 5-α reductase inhibitors
- Effects of 5‐alpha reductase inhibitors on lung function: A reason for discontinuation duringCOVID‐19 pandemic?
- 5-alpha Reductase inhibitors and risk of male breast cancer: a systematic review and meta-analysis
- Association Between 5-Alpha Reductase Inhibitor Use and The Risk of Depression: A Meta-Analysis.
- Bladder cancer survival in men using 5-alpha-reductase inhibitors
- The Effects of Oral 5-alpha Reductase Inhibitors on Penile Intracavernosal Pressures and Penile Morphology in Rat Model.
- Re: Risk of Erectile Dysfunction Associated with Use of 5α-Reductase Inhibitors for Benign Prostatic Hyperplasia or Alopecia: Population Based Studies Using the Clinical Practice Research Datalink
- Association Between 5α-Reductase Inhibitors and Prostate Cancer Mortality
- Design of Liposome Formulations for CRISPR/Cas9 Enzyme Immobilization: Evaluation of 5-Alpha-Reductase Enzyme Knockout for Androgenic Disorders
- Association of long-term 5α-reductase inhibitor use with survival in men with renal cell carcinoma: a nationwide population-based cohort study
- Risk of Type 2 Diabetes Mellitus in New Users of 5-Alpha Reductase Inhibitors: A Nationwide Historical Cohort Study
- 5-alpha reductase inhibitors: New evidences on benefits and harms beyond benign prostatic hyperplasia
- Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink
- HPLC characterization, molecular docking, QSAR and molecular dynamics simulation of Alstonia boonei phytochemical analogs as potent 5-alpha reductase inhibitors
- Long-term Oral Administration of 5α-reductase Inhibitor Attenuates Erectile Function by Inhibiting Autophagy and Promoting Apoptosis of Smooth Muscle Cells in Corpus Cavernosum of Aged Rats
- Male Breast Cancer and 5α-Reductase Inhibitors Finasteride and Dutasteride
- Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
- 5α-Reductase Inhibitors (5ARIs) and Male Reproduction
- PCPT, MTOPS and the use of 5ARIs: a Canadian consensus regarding implications for clinical practice
- Impact of Alpha Blockers, 5-alpha Reductase Inhibitors and Combination Therapy on Sexual Function
- Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study
- The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
- The connection of 5-alpha reductase inhibitors to the development of depression
- 5ARIs and PSA: Evidences